Nicotine Polacrilex

Smoke, nicotine

Treatment

2 FDA approvals

2 Active Studies for Nicotine Polacrilex

What is Nicotine Polacrilex

Nicotine

The Generic name of this drug

Treatment Summary

Nicotine is an extremely toxic chemical found in tobacco smoke. It activates nerve cells and blocks signals from being sent between them. Nicotine is especially dangerous because of its presence in cigarettes and other tobacco products.

equate Nicotine

is the brand name

image of different drug pills on a surface

Nicotine Polacrilex Overview & Background

Brand Name

Generic Name

First FDA Approval

How many FDA approvals?

equate Nicotine

Nicotine

1990

1005

Approved as Treatment by the FDA

Nicotine, otherwise called equate Nicotine, is approved by the FDA for 2 uses which include Smoke and nicotine .

Smoke

Helps manage Smoking cessation therapy

nicotine

Helps manage Withdrawal Nicotine

Effectiveness

How Nicotine Polacrilex Affects Patients

Nicotine, the main chemical in tobacco products, binds to certain receptors in the brain, nerves, and other organs. It can cause a stimulating effect and a feeling of reward. Nicotine also leads to increased heart rate, higher blood pressure, and constricted blood vessels. Nicotine replacements in the form of inhalers and patches are used to help people quit smoking. Nicotine is a very addictive substance and is classified as a stimulant.

How Nicotine Polacrilex works in the body

Nicotine stimulates the body in two ways. First, it binds to nicotinic acetylcholine receptors in the brain, causing dopamine to be released. This dopamine release is responsible for the euphoric and addictive properties of nicotine. Secondly, nicotine binds to nicotinic acetylcholine receptors in the adrenal medulla, which triggers the release of epinephrine. Epinephrine causes increases in blood pressure, heart rate, and blood sugar levels.

When to interrupt dosage

The suggested measure of Nicotine Polacrilex is contingent upon the identified ailment. The amount of dosage is contingent upon the procedure of administration specified in the table below.

Condition

Dosage

Administration

nicotine

, 1.4 mg/hour, 14.0 mg, 0.7 mg/hour, 2.1 mg/hour, 7.0 mg, 21.0 mg, 4.0 mg, 2.0 mg, 1.0 mL/mL, 1.0 mg/mg, 114.0 mg, 78.0 mg, 36.0 mg, 10.0 mg/mL, 0.18 mg/mg, 0.15 mg/mg, 0.2 mg/mg, 2.0 mg/hour, 4.0 mg/hour, 8.0 mg, 2.5 mg/hour, 0.06 mg/mg, 0.12 mg/mg, 0.21 mg/mg

Transdermal, Patch, extended release, Patch, extended release - Transdermal, Topical, Patch, extended release - Topical, , Oral, Gum, chewing, Gum, chewing - Oral, Gum, chewing - Buccal, Lozenge - Oral, Respiratory (inhalation), Inhalant - Respiratory (inhalation), Inhalant, Powder - Oral, Liquid, Powder, Patch - Transdermal, Patch, Lozenge, Kit, Dental; Oral, Patch - Topical, Buccal, Kit - Transdermal, Liquid - Oral, Nasal, Spray, metered - Nasal, Spray, metered

Smoke

, 1.4 mg/hour, 14.0 mg, 0.7 mg/hour, 2.1 mg/hour, 7.0 mg, 21.0 mg, 4.0 mg, 2.0 mg, 1.0 mL/mL, 1.0 mg/mg, 114.0 mg, 78.0 mg, 36.0 mg, 10.0 mg/mL, 0.18 mg/mg, 0.15 mg/mg, 0.2 mg/mg, 2.0 mg/hour, 4.0 mg/hour, 8.0 mg, 2.5 mg/hour, 0.06 mg/mg, 0.12 mg/mg, 0.21 mg/mg

Transdermal, Patch, extended release, Patch, extended release - Transdermal, Topical, Patch, extended release - Topical, , Oral, Gum, chewing, Gum, chewing - Oral, Gum, chewing - Buccal, Lozenge - Oral, Respiratory (inhalation), Inhalant - Respiratory (inhalation), Inhalant, Powder - Oral, Liquid, Powder, Patch - Transdermal, Patch, Lozenge, Kit, Dental; Oral, Patch - Topical, Buccal, Kit - Transdermal, Liquid - Oral, Nasal, Spray, metered - Nasal, Spray, metered

Warnings

There are 20 known major drug interactions with Nicotine Polacrilex.

Common Nicotine Polacrilex Drug Interactions

Drug Name

Risk Level

Description

Aminophylline

Major

The metabolism of Aminophylline can be increased when combined with Nicotine.

Cisplatin

Major

The serum concentration of Cisplatin can be increased when it is combined with Nicotine.

Clofarabine

Major

The serum concentration of Clofarabine can be increased when it is combined with Nicotine.

Cyclophosphamide

Major

The metabolism of Cyclophosphamide can be decreased when combined with Nicotine.

Dalfampridine

Major

The serum concentration of Dalfampridine can be increased when it is combined with Nicotine.

Nicotine Polacrilex Toxicity & Overdose Risk

Overdosing on the drug can cause nausea, stomach cramps, vomiting, diarrhea, sweating, blushing, dizziness, blurred vision and hearing, confusion, weakness, heart palpitations, changes in breathing rate, and low blood pressure. The lowest toxic dose for mice is 24mg/kg taken orally.

image of a doctor in a lab doing drug, clinical research

Nicotine Polacrilex Novel Uses: Which Conditions Have a Clinical Trial Featuring Nicotine Polacrilex?

Five active clinical trials are investigating the potential of Nicotine Polacrilex to provide relief from Nicotine addiction.

Condition

Clinical Trials

Trial Phases

Smoke

0 Actively Recruiting

nicotine

2 Actively Recruiting

Not Applicable, Phase 1, Phase 2

Nicotine Polacrilex Reviews: What are patients saying about Nicotine Polacrilex?

5

Patient Review

8/8/2012

Nicotine Polacrilex for Nicotine Addiction

I've been using this treatment for 5 years now and it's really helped me.

5

Patient Review

11/15/2013

Nicotine Polacrilex for Nicotine Addiction

I was 15 when a friend gave me this from a gas station. It worked great for my addiction.

5

Patient Review

4/27/2008

Nicotine Polacrilex for Stop Smoking

5

Patient Review

1/6/2009

Nicotine Polacrilex for Stop Smoking

I've been chewing this product for two years now. Is it dangerous?

4.7

Patient Review

10/14/2010

Nicotine Polacrilex for Stop Smoking

I was able to successfully quit smoking by using Chantix. I started taking it when my cravings were really bad and now, two years later, I still take the lozenges or gum occasionally. Will this have any negative effect on my organs?

4.7

Patient Review

5/6/2009

Nicotine Polacrilex for Stop Smoking

I found that using 2mg lozenges on a daily basis helped me to significantly reduce the dizziness, irritability and problems with concentration that I experienced when quitting nicotine (approximately 10-12 lozenges per day for the first three weeks).

3.3

Patient Review

3/29/2022

Nicotine Polacrilex for Symptoms because a person has Stopped Smoking

I experienced some dizziness and gastrointestinal distress while taking this medication. It was bad enough that I couldn't work. However, it did help me quit smoking, so I still think it's effective overall.

Patient Q&A Section about nicotine polacrilex

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Is Nicotine polacrilex safe?

"If a child sucks or chews on a used or unused lozenge or piece of gum containing Leader Nicotine Polacrilex, it could be fatal. Seek emergency medical attention if this happens. Symptoms of an overdose may include severe dizziness, nausea, vomiting, diarrhea, weakness, and fast heart rate."

Answered by AI

Is Nicotine polacrilex the same as nicotine?

"Nicotine Polacrilex is a smoking cessation aid that comes in generic and brand name forms. The generic form is called Nicotine Polacrilex, and the brand names are Nicotrol NS, Nicorelief, and Nicorette. Nicotine Polacrilex helps reduce withdrawal symptoms for people who are trying to quit smoking."

Answered by AI

What is Nicotine polacrilex made of?

"Nicotine polacrilex is a version of nicotine that is bound to an ion-exchange resin. This type of nicotine is often used in gums and hard lozenges that are meant to help people quit smoking. Products that contain nicotine polacrilex are often part of smoking cessation programs."

Answered by AI

Does Nicotine polacrilex have nicotine?

"The active ingredient in each piece of gum is nicotine polacrilex, which is equivalent to 4 mg of nicotine. This gum is a stop smoking aid."

Answered by AI

Clinical Trials for Nicotine Polacrilex

Image of Rush University Medical Center in Chicago, United States.

NRT + Quit Practice Strategies for Smoking Cessation

18+
All Sexes
Chicago, IL

Tobacco use disorder is a chronic, relapsing health condition that necessitates a chronic care approach. However, traditional smoking cessation treatment programs allocate nearly all their resources only to those smokers who are willing to set a quit date. This is problematic because few smokers are ready to set a quit date at any given time, and a smoker's stated intention to quit can change rapidly. One novel potential treatment strategy is to foster practice quitting (PQ), defined as attempting to not smoke for a few hours or days, without pressure or expectation to permanently quit. Although a growing body of evidence supports the role of practice quitting in fostering permanent quit attempts and cessation, there is a significant knowledge gap regarding which treatment strategies should be used to engage smokers in practice quitting. The proposed study will test the role of PQ counseling vs. Motivational Interviewing (MI) counseling, and NRT sampling (four-week supply of nicotine lozenges and patches) vs. none.

Phase 1 & 2
Recruiting

Rush University Medical Center

Amanda Mathew, PhD

Image of The Ottawa Hospital General Campus in Ottawa, Canada.

Quit Card Intervention for Cigarette Addiction

18+
All Sexes
Ottawa, Canada

The INITIATE Study is a randomized controlled trial that is testing an intervention designed to increase long-term abstinence among tobacco smokers seen in emergency departments (ED) and other high-volume hospital and community ambulatory care settings. The intervention includes a behavioural incentive and tailored follow-up support on long-term smoking abstinence, health, healthcare utilization, and cost. Tobacco-related illnesses cost the healthcare system millions each year. Quitting smoking improves smoking-related outcomes, like the onset or management of heart disease, stroke, lung diseases, and several cancers. There are approximately 16 million visits to Canadian EDs each year; an estimated 3-4 million of these involve smokers. Effective quit smoking interventions exist, but are underutilized. Few hospital EDs, community healthcare centers, and other inpatient and outpatient clinics in Canada offer tobacco-use interventions. In order for clinicians to offer quit smoking support, interventions need to be simple given the realities of these high-volume environments. Considering that stopping smoking improves health outcomes, that tobacco-use is an important cause of preventable ED use, and the volume of smokers, Canadian EDs and other high-volume hospital and community ambulatory care settings are a missed opportunity in the initiation of quit smoking support. Our intervention has been designed to optimize uptake and smoking abstinence by including the most effective evidence-based behavioural and drug-related approaches, removing specific barriers and challenges that smokers face when trying to quit (e.g., affordability, low confidence and motivation), while packaging the intervention in a quick-to-initiate manner, making it ideal for fast-paced, complex environments.

Recruiting
Has No Placebo

The Ottawa Hospital General Campus (+5 Sites)

Kerri-Anne Mullen, PhD